Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

PET/MRI in the Diagnosis of Pediatric Chronic Pain

[18F]FTC-146 is a sigma-1 receptor detector and is an experimental radiotracer. Several studies have implicated involvement of sigma-1 receptors in generation and perpetuation of chronic pain conditions, while others are investigating anti sigma-1 receptor drugs for treatment of chronic pain. Using [18F]-FTC-146 and PET/MRI, we hope to learn what is the best approach to identify the source of pain generation and characterize the disease in pediatric patients with chronic pain.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: [18F]FTC-146

Eligibility


Inclusion Criteria:

   - 11-18 years old.

   - Chronic pain (nociceptive, neuropathic or mixed pain) lasting at least 2 months.

   - Pain level of at least 4/10 on a 0-10 Comparative Pain Scale (reported at time of
   screening).

   - Covid Vaccination status: Vaccinated or unvaccinated subjects who received a negative
   test result from the Covid test within 72 hours of the scan.

Exclusion Criteria:

   - MRI incompatible

   - Pregnant or nursing

   - Non-English speaker

   - Claustrophobic

Ages Eligible for Study

11 Years - 18 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting